2014
DOI: 10.1016/j.bbr.2013.10.025
|View full text |Cite
|
Sign up to set email alerts
|

Pyrroloquinoline quinone prevents MK-801-induced stereotypical behavior and cognitive deficits in mice

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

1
2
0

Year Published

2015
2015
2022
2022

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 16 publications
(3 citation statements)
references
References 60 publications
1
2
0
Order By: Relevance
“…1 ). The results are supported by previous studies, using MK-801 treatment in mice 54 and hypoxia treatment in rats 55 , which proved that PQQ would prevent the cognitive deficit resulting from the oxidative stress.…”
Section: Discussionsupporting
confidence: 86%
See 1 more Smart Citation
“…1 ). The results are supported by previous studies, using MK-801 treatment in mice 54 and hypoxia treatment in rats 55 , which proved that PQQ would prevent the cognitive deficit resulting from the oxidative stress.…”
Section: Discussionsupporting
confidence: 86%
“…Some studies had already confirmed that PQQ prevents oxidative damage in the brain and reduces the cognitive deficit caused by oxidative stress in rats during aging 52 . In our previous study, we found that PQQ may be converted into a derivative by binding with amino acid, which is beneficial to several pathological processes 53 , 54 . However, which derivative promotes antioxidant in aging brain and the underlying mechanism is yet unclear.…”
Section: Discussionmentioning
confidence: 99%
“…To assess if such AIS plasticity actually occur in schizophrenia, we used postnatal MK-801 (an NMDA receptor antagonist) model. Transient exposure to MK-801 during the neonatal period causes behavioral changes in rodents such as hyperlocomotion, stereotyped behavior, sensorimotor gating, and cognitive deficits representing schizophrenia-like symptoms (Feinstein & Kritzer, 2013;Furuie, Yamada, & Ichitani, 2013;Nozari, Shabani, Hadadi, & Atapour, 2014, Nozari, Mansouri, Shabani, Nozari, & Atapour, 2015Nozari, Shabani, Farhangi, Mazhari, & Atapour, 2015;Zhou, Chen, Hu, Mao, & Kong, 2013). Underlying these behavioral changes are a decrease in the function of different neurotransmitter systems such as glutamatergic, dopaminergic, and GABAergic system (Abekawa, Ito, Nakagawa, & Koyama, 2007;Hoftman & Lewis, 2011;Jones, Corbin, & Huntsman, 2014;Weinstein et al, 2016).…”
mentioning
confidence: 99%